Trump's FDA pick linked to Joe Rogan-backed psychedelic policy

Donald Trump has nominated Dr. Heidi Overton to lead the Food and Drug Administration (FDA), a move that highlights her role in promoting psychedelic drug research, according to a report by the Daily Mail. Overton, a top aide in the White House and a medical doctor, played a significant part in advancing a policy supported by podcaster Joe Rogan, which aims to ease access to psychedelic medicines such as ibogaine and LSD.

Overton's Role in Psychedelic Policy

Dr. Overton, who serves as the deputy director of the White House Domestic Policy Council, was instrumental in fast-tracking an executive order signed by Trump to accelerate research into psychedelic drugs. The Wall Street Journal previously reported that Rogan had influenced Trump by sending him statistics on ibogaine's potential to reduce opioid addiction. In response, Trump reportedly expressed enthusiasm and suggested pursuing FDA approval.

Nomination Details

Trump announced Overton's nomination on Wednesday, though she still requires Senate confirmation. Overton has been a key figure in Trump's administration, supporting his objectives of faster drug approvals and lower medication costs. Health Secretary Robert F. Kennedy Jr. praised her judgment and commitment to public service.

Senate Confirmation Challenges

Overton's nomination faces scrutiny, particularly from Louisiana Republican Senator Bill Cassidy, who chairs the Senate Health, Education, Labor and Pensions Committee. Cassidy, a physician, expressed concerns about Overton's managerial experience and her involvement in a controversial vaccine order. Additionally, Washington Senator Patty Murray criticized Overton as an "anti-abortion extremist," questioning her suitability for the FDA role.

Why it matters

The nomination of Dr. Overton is significant as it underscores the growing interest in psychedelic research within the U.S. government. If confirmed, her leadership could influence the regulatory landscape for psychedelic substances, potentially impacting drug approval processes and research funding.

Dr. Overton's educational background includes medical training at the University of New Mexico and a doctoral degree in clinical investigation from Johns Hopkins University.